CN101653587B - Tangerine peel buccal tablets, oral disintegrating tablets and application thereof - Google Patents
Tangerine peel buccal tablets, oral disintegrating tablets and application thereof Download PDFInfo
- Publication number
- CN101653587B CN101653587B CN2008100302881A CN200810030288A CN101653587B CN 101653587 B CN101653587 B CN 101653587B CN 2008100302881 A CN2008100302881 A CN 2008100302881A CN 200810030288 A CN200810030288 A CN 200810030288A CN 101653587 B CN101653587 B CN 101653587B
- Authority
- CN
- China
- Prior art keywords
- pericarpium citri
- citri reticulatae
- tangerine peel
- tablets
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003826 tablet Substances 0.000 title claims abstract description 20
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 18
- 241000675108 Citrus tangerina Species 0.000 title abstract 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 229940046011 buccal tablet Drugs 0.000 claims description 15
- 210000000214 mouth Anatomy 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 108010011485 Aspartame Proteins 0.000 claims description 9
- 235000010357 aspartame Nutrition 0.000 claims description 9
- 239000000605 aspartame Substances 0.000 claims description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 9
- 229960003438 aspartame Drugs 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229920003081 Povidone K 30 Polymers 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 201000003152 motion sickness Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 241000234314 Zingiber Species 0.000 abstract description 12
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 12
- 235000008397 ginger Nutrition 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 12
- 230000008673 vomiting Effects 0.000 abstract description 12
- 208000002173 dizziness Diseases 0.000 abstract description 9
- 239000000654 additive Substances 0.000 abstract description 8
- 206010019233 Headaches Diseases 0.000 abstract description 5
- 231100000869 headache Toxicity 0.000 abstract description 5
- 206010041349 Somnolence Diseases 0.000 abstract description 4
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 abstract description 4
- 229960004993 dimenhydrinate Drugs 0.000 abstract description 4
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 210000004916 vomit Anatomy 0.000 abstract description 4
- 210000002460 smooth muscle Anatomy 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract description 2
- 102000002852 Vasopressins Human genes 0.000 abstract description 2
- 108010004977 Vasopressins Proteins 0.000 abstract description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract description 2
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 2
- 229960003726 vasopressin Drugs 0.000 abstract description 2
- 206010028813 Nausea Diseases 0.000 abstract 2
- 230000008693 nausea Effects 0.000 abstract 2
- 206010021750 Infantile Spasms Diseases 0.000 abstract 1
- 230000002457 bidirectional effect Effects 0.000 abstract 1
- 230000035922 thirst Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 11
- 206010047700 Vomiting Diseases 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 241000207199 Citrus Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- QYZBCWXZSYTIOY-UHFFFAOYSA-N Mercuric oxide Chemical compound [O-2].[Hg+2] QYZBCWXZSYTIOY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- CLJTZNIHUYFUMR-UHFFFAOYSA-M sodium;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CLJTZNIHUYFUMR-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000000200 vestibular neuronitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to tangerine peel buccal tablets, oral disintegrating tablets and application thereof. 1,000 tangerine peel buccal tablets or 1,000 oral disintegrating tablets are prepared from the following components and pharmaceutically acceptable additives: 120 to 220 grams of tangerine peel and 380 to 480 grams of fresh ginger. The tangerine peel has bidirectional regulation function on gastrointestinal smooth muscles so as to influence the gastrointestinal motility; the ginger can inhibit the central nervous system to release vasopressin so as to relive electrogastric hypsarrhythmia in motion sickness and symptoms such as nausea, vomit and the like; and when the tangerine peel and the ginger are combined, the effect of the combination is superior to that of dimenhydrinate, and the combination has no adverse reaction such as drowsiness, dizziness, headache, thirst, nausea, vomit, epigastric region discomfort and the like.
Description
Technical field
The present invention relates to a kind of Pericarpium Citri Reticulatae buccal tablet, oral cavity disintegration tablet and application thereof.
Background technology
Pericarpium Citri Reticulatae derives from Rutaceae plant Citrus, reticulata, Blanco and carries the mature peel of training mutation, Ming Dynasty's Li Shizhen (1518-1593 A.D.) cloud: " then mend with tonic, then rush down with cathartic, then rise with Hydrargyri Oxydum Rubrum, then fall with falling medicine.Spleen is the mother of Primordial Qi, and lung is label of taking the photograph gas, so Pericarpium Citri tangerinae is two medicines through edema caused by disorder of QI, but with join and the reinforcing and reducing lifting also ".So the Pericarpium Citri Reticulatae preparation is widely used in the disease treatments such as respiratory tract, digestive tract.The Pericarpium Citri Reticulatae preparation also has fine effect aspect cardiovascular, endocrine, anticancer, defying age, skin maintenance, the nutrition tonify deficiency in recent years.
The Pericarpium Citri Reticulatae preparation formulation mainly contains powder, mixture, oral liquid, medicated wine, electuary, tablet, injection etc., and Pericarpium Citri Reticulatae is used as medicine to be had direct pulverize and extract its active ingredient dual mode.
Since social fast-developing, an important component part during the vehicles become the living words of people and work.People's trip be unable to do without the vehicles.These vehicles have brought also for the people who takes and do not accommodate misery when bringing convenience to people.Topmost malaise symptoms when motion sickness is exactly people's riding public transportation means.Motion sickness is a kind of because the syndrome that motion stimulate to cause, and its symptom is based on vestibule vegetative nerve dysfunctions such as dizzy, nauseating, vomitings, and epidemiological study shows that about 80% people experienced motion sickness; In manned space flight, motion sickness appearred in 35%～67% spacefarer.
Modern medicine thinks, the generation of motion sickness and the vehicles are produced when motion jolt, wave or the accelerated motion repeatedly of form such as rotation relevant.Clinical control motion sickness medicine dimenhydrinate commonly used plays a role by suppressing vomiting center, but untoward reaction such as common drowsiness, dizzy, headache, xerostomia, nauseating, vomiting and epigastric region discomfort; Hypertension, hyperthyroidism, cardiopalmus patient avoid usefulness; Glaucoma, neonate, premature infant, newborn woman etc. avoid usefulness.Also have some folk prescriptions among the people to be used to prevent and treat motion sickness, but these method effect instabilities, not remarkable, perhaps medication inconvenience.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art part, a kind of Chinese medicine preparation of preventing and treating motion sickness is provided, this Chinese medicine preparation taking convenience, taste is good, is free from side effects.
Technical scheme of the present invention is: a kind of Pericarpium Citri Reticulatae buccal tablet/oral cavity disintegration tablet comprises following each component and pharmaceutically acceptable additives:
Pericarpium Citri Reticulatae 140-200 gram
Fresh ginger 280-400 gram
Make 1000 altogether.
Preferably, Pericarpium Citri Reticulatae buccal tablet/oral cavity disintegration tablet of the present invention comprises following each component and pharmaceutically acceptable additives:
Pericarpium Citri Reticulatae 150-190 gram
Fresh ginger 300-380 gram
Make 1000 altogether.
Preferably, Pericarpium Citri Reticulatae buccal tablet/oral cavity disintegration tablet of the present invention comprises following each component and pharmaceutically acceptable additives:
Pericarpium Citri Reticulatae 160-180 gram
Fresh ginger 320-360 gram
Make 1000 altogether.
Preferably, Pericarpium Citri Reticulatae buccal tablet/oral cavity disintegration tablet of the present invention comprises following each component and pharmaceutically acceptable additives:
Pericarpium Citri Reticulatae 170-175 gram
Fresh ginger 340-350 gram
Make 1000 altogether.
Preferably, Pericarpium Citri Reticulatae buccal tablet of the present invention is made up of following each component:
Pericarpium Citri Reticulatae 173.0 grams
Fresh ginger 346.0 grams
Icing Sugar 200.8
Soluble starch 200.8 grams
Citric acid 16.0 grams
Aspartame 6.0 grams
Flavoring orange essence 3.0 grams
Magnesium stearate is an amount of
Make 1000 altogether.
Preferably, oral cavity disintegration tablet of the present invention is made up of following each component:
Pericarpium Citri Reticulatae 173.0g
Rhizoma Zingiberis Recens 346.0g
Microcrystalline Cellulose 154.0g
Polyvinylpolypyrrolidone 46.1g
Low-substituted hydroxypropyl cellulose 39.2g
Mannitol 51.2g
Citric acid 39.2g
Sodium bicarbonate 39.2g
Aspartame 5.12g
Micropowder silica gel 10.2g
5% 30 POVIDONE K 30 BP/USP
30Ethanol solution is an amount of
Make 1000 altogether.
The preparation method of Pericarpium Citri Reticulatae buccal tablet of the present invention or Orally-disintegrating tablet is as follows: take by weighing the Pericarpium Citri Reticulatae medical material of ormal weight, add suitable quantity of water and decoct secondary, each 1-2 hour, collecting decoction also filtered, and filtrate is condensed into thick paste; The Rhizoma Zingiberis Recens that takes by weighing ormal weight extracts volatile oil, and the aqueous solution after the distillation filters, and filtrate is condensed into thick paste; Pericarpium Citri Reticulatae thick paste and Rhizoma Zingiberis Recens thick paste merge, and drying is ground into fine powder; Add medically acceptable disintegrating agent and/or other additives, mixing is granulated, drying, and granulate sprays into Rhizoma Zingiberis Recens volatile oil, tabletting.
Motion sickness belongs to " vertigo " category in theory of Chinese medical science.Its cause of disease mostly is deficiency of marrow-reservoir, deficiency of qi and blood and stagnation of turbid phlegm in middle-JIAO.When inducements such as rotating, wave, jolt influenced, it was disorderly contrary then to cause mechanism of qi, and lifting is become estranged; Or upward adverse flow of phlegm and falling ill, the symptom of mechanism of qi superinverses such as uncomfortable in chest, nauseating, vomiting, stomach discomfort appears clinically.The Pericarpium Citri tangerinae regulating qi-flowing for harmonizing stomach, the Rhizoma Zingiberis Recens expelling cold to relieve vomiting and and use it, make that sun is logical cold to be gone, gastric qi and falling is then retched, is vomited and the cold spontaneous recovery of fainting.Have experiment to show that symptoms of emesis and gastrointestinal smooth muscle functional status have close ties, and Pericarpium Citri Reticulatae have dual regulation to gastrointestinal smooth muscle, influences gastrointestinal motility; Rhizoma Zingiberis Recens can discharge vasopressin by suppressing the central nervous system, thereby the stomach when alleviating motion sickness electricity arhythmicity and feel sick, symptom such as vomiting, the two synergy, its effect is better than dimenhydrinate, and do not have drowsiness, dizzy, headache, xerostomia, feel sick, untoward reaction such as vomiting and epigastric region discomfort.
The specific embodiment
Pericarpium Citri Reticulatae buccal tablet/oral cavity disintegration tablet of the present invention comprises Pericarpium Citri Reticulatae, fresh ginger and/or pharmaceutically acceptable disintegrating agent and other additives, and the consumption of additives is not had special requirement, as long as in the acceptable scope of materia medica.The consumption of disintegrating agent is generally the 10-30% of whole raw material weights, and pharmaceutically Chang Yong disintegrating agent all can use, and preferred polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, citric acid and sodium bicarbonate are mixed to be used.
Embodiment 1: a kind of Pericarpium Citri Reticulatae buccal tablet, composed as follows:
Pericarpium Citri Reticulatae 173.0 grams
Fresh ginger 346.0 grams
Icing Sugar 200.8 grams
Soluble starch 200.8 grams
Citric acid 16.0 grams
Aspartame 6.0 grams
Flavoring orange essence 3.0 grams
Magnesium stearate is an amount of
Take by weighing each component by above-mentioned prescription.The Pericarpium Citri Reticulatae medical material is added suitable quantity of water decoct secondary, each 2 hours, collecting decoction also filtered, and filtrate is condensed into thick paste (60 ℃ of relative density 1.0-1.10); Rhizoma Zingiberis Recens is extracted volatile oil, and the aqueous solution after the distillation filters, and filtrate is condensed into thick paste (60 ℃ of relative density 1.0-1.10); Pericarpium Citri Reticulatae thick paste and Rhizoma Zingiberis Recens thick paste merge, and drying is ground into fine powder; Add Icing Sugar 200.8 grams, soluble starch 200.8 grams, citric acid 16 grams, aspartame 6.0 grams, flavoring orange essence 3.0 grams, mixing is granulated, and cold drying sprays into Rhizoma Zingiberis Recens volatile oil, and it is an amount of to add magnesium stearate, mixing, tabletting.Make 1000 every heavy 0.5 gram altogether.
The invention provides other embodiment following (unit: restrain) of Pericarpium Citri Reticulatae buccal tablet:
| Sequence number | Pericarpium Citri Reticulatae | Fresh ginger | Icing Sugar | Soluble starch | Citric acid | Aspartame | Flavoring orange essence | Magnesium stearate |
| 2 | 140 | 380 | 200 | 200 | 14 | 8 | 1 | In right amount |
| 3 | 150 | 370 | 210 | 190 | 17 | 5 | 3 | In right amount |
| 4 | 160 | 355 | 220 | 180 | 18 | 4 | 4 | In right amount |
| 5 | 162 | 358 | 200 | 200 | 16 | 6 | 2 | In right amount |
| 6 | 170 | 350 | 225 | 175 | 15 | 7 | 5 | In right amount |
| 7 | 175 | 345 | 230 | 170 | 14 | 8 | 1 | In right amount |
| 8 | 176 | 344 | 220 | 180 | 17 | 5 | 3 | In right amount |
The preparation method of last each embodiment of table is with embodiment 1, and each embodiment all makes 1000 in tablet.
Embodiment 9: a kind of Pericarpium Citri Reticulatae oral cavity disintegration tablet, and it is composed as follows:
Pericarpium Citri Reticulatae 173.0g
Rhizoma Zingiberis Recens 346.0g
Microcrystalline Cellulose 154.0g
Polyvinylpolypyrrolidone 46.1g
Low-substituted hydroxypropyl cellulose 39.2g
Mannitol 51.2g
Citric acid 39.2g
Sodium bicarbonate 39.2g
Aspartame 5.12g
Micropowder silica gel 10.2g
5% 30 POVIDONE K 30 BP/USP
30Ethanol solution is an amount of
Make 1000 altogether
Take by weighing each component by above-mentioned prescription.The Pericarpium Citri Reticulatae medical material is added suitable quantity of water decoct secondary, each 2 hours, collecting decoction also filtered, and filtrate is condensed into thick paste (60 ℃ of relative density 1.0-1.10); Rhizoma Zingiberis Recens is extracted volatile oil, and the aqueous solution after the distillation filters, and filtrate is condensed into thick paste (60 ℃ of relative density 1.0-1.10); Pericarpium Citri Reticulatae thick paste and Rhizoma Zingiberis Recens thick paste merge, and drying is ground into impalpable powder; Add microcrystalline Cellulose 154g, polyvinylpolypyrrolidone 46.1g, low-substituted hydroxypropyl cellulose 39.2g, mannitol 51.2g, citric acid 39.2g, sodium bicarbonate 39.2g, aspartame 5.12g, micropowder silica gel 6.8g, mixing adds 5% 30 POVIDONE K 30 BP/USP
30Ethanol solution is an amount of, and 40 mesh sieves are granulated, and drying sprays into Rhizoma Zingiberis Recens volatile oil, adds micropowder silica gel 3.4g, mixing, and tabletting is made 1000 every heavy 0.45 gram altogether.
Other embodiment of Pericarpium Citri Reticulatae oral cavity disintegration tablet provided by the invention following (unit: restrain):
| Sequence number | Pericarpium Citri Reticulatae | Fresh ginger | Microcrystalline Cellulose | Polyvinylpolypyrrolidone | Low-substituted hydroxypropyl cellulose | Mannitol | Citric acid | Sodium bicarbonate | Aspartame | Micropowder silica gel | 5% 30 POVIDONE K 30 BP/USP, 30 ethanol solutions |
| 10 | 140 | 380 | 150 | 47 | 38 | 50 | 41 | 40 | 5 | 12 | In right amount |
| 11 | 150 | 370 | 154 | 44 | 39 | 52 | 39 | 38 | 6 | 12 | In right amount |
| 12 | 160 | 355 | 150 | 47 | 38 | 50 | 41 | 40 | 5 | 12 | In right amount |
| 13 | 165 | 358 | 154 | 44 | 39 | 52 | 39 | 38 | 6 | 12 | In right amount |
| 14 | 170 | 350 | 150 | 47 | 38 | 50 | 41 | 40 | 5 | 12 | In right amount |
| 15 | 175 | 345 | 154 | 44 | 39 | 52 | 39 | 38 | 6 | 12 | In right amount |
The preparation method of last each embodiment of table is with embodiment 9, and each embodiment all makes 1000 in tablet, every 0.45 gram.
Be the clinical application research report of Pericarpium Citri Reticulatae oral cavity disintegration tablet of the present invention below:
The chance that the inventor utilizes the student of Jiangxi Chinese medicine higher junior college and Jiangmen, Guangdong Province Chinese medicine school to have a winter vacation and go home and return to school has been carried out the clinical observation of prevention of motion sickness to embodiment 9 described Pericarpium Citri Reticulatae oral cavity disintegration tablets, is reported as follows:
1 object and method
1.1 case is selected:
1. the experimenter must be the passenger of riding public transportation means steamer, automobile.2. the riding public transportation means time is no less than 1h.3. similarly history of attack is previously arranged repeatedly during riding public transportation means.To Meniere's disease, vestibular neuritis, head position vertigo, psychogenic vertigo person and have a heart disease, hypertension, blood patient, do not list range of observation in.
1.2 physical data:
This is organized 113 examples and is this student outside school.Treatment is organized in 71 examples, male 29 examples, women 42 examples; Minimum 15 years old of age, maximum 22 years old, average 18.6 years old.In matched group 42 examples, male 19 examples, women 23 examples; Minimum 14 years old of age, maximum 21 years old, average 18.1 years old.Two groups of physical data are learned processing by statistics, and there was no significant difference has comparability.
1.3 grouping and medication:
All objects of observation all are divided into treatment group, matched group at random.The treatment group gives the Pericarpium Citri Reticulatae buccal tablet of embodiment 1, and (ship) preceding 1h is put 1 import every 20min by bus, swallows after the disintegrate; Car (ship) starts the back put 1 import every 10 minutes, swallowed after the dissolving.
Matched group: dimenhydrinate sheet, each 50mg, decoction being taken at a draught in the by bus preceding 30min.When the vehicles arrived at a station, promptly came to an end the course of treatment.
1.4 curative effect determinate standard:
1. produce effects: whole process is more comfortable, and no dizzy, nauseating, symptoms of emesis has obvious appetite person, or the sense gastral cavilty do not relax, and appetite does not subtract the person slightly.
2. effective: whole process has nauseating symptom, reduces but do not vomit or vomit number of times, and is dizzy, weak, saliva is increased or pale complexion, sx such as uncomfortable in chest, nervous.
3. invalid: carsick (ship) symptom no change.
Observed data adopts the Ridit check to carry out statistical analysis, is that difference has significance with P＜0.05.
2 experimental results
2.1 two groups of experimenter's general curative effects relatively see Table 1.
Table 1 liang group experimenter general curative effect is (unit: example, %) relatively
As shown in Table 1, analyze through Ridit, and u=1.486 (P〉0.05), prompting treatment group curative effect and matched group there was no significant difference.Illustrate that said preparation can replace the relatively Western medicine preparation of outstanding anti-motion sickness class of side effect clinically.
2.2 symptoms and therapeutic effect: matched group dizziness, headache, three kinds of doing well,improvings such as weak are not obvious, and the treatment group can effectively alleviate symptoms such as nauseating, dizzy, weak and stomach discomfort, but two groups all can effectively alleviate vomiting, symptom uncomfortable in chest.
2.3 experimenter's medication impression: the matched group medication is convenient, but with after certain untoward reaction such as drowsiness, dizzy, headache, xerostomia etc. are arranged; The treatment group except that indivedual experimenters to the Rhizoma Zingiberis Recens flavor incompatibility, think mostly almost to have no adverse reaction good mouthfeel.
3 conclusions
The Pericarpium Citri Reticulatae buccal tablet can dissolve, disperse after meeting saliva, and the patient need not water can obey medicine down smoothly.Compare with ordinary preparation, taking convenience is arranged, absorb fast, bioavailability is high, to advantages such as digestion mucous membrane zest are little, to medication under the hydropenia condition or to take Bendectin more suitable.
Pericarpium Citri Reticulatae buccal tablet or oral cavity disintegration tablet medicine are eaten same usefulness, have cold expelling and regulate the flow of vital energy, and the effect of regulating the stomach and sending down the abnormal ascending QI is used for the control of motion sickness, have the convenience of taking medicine, taste characteristics good, evident in efficacy, and almost are free from side effects.
Claims (1)
1. Pericarpium Citri Reticulatae buccal tablet/oral cavity disintegration tablet is characterized in that being made up of following each component:
Pericarpium Citri Reticulatae 173.0g
Rhizoma Zingiberis Recens 346.0g
Microcrystalline Cellulose 154.0g
Polyvinylpolypyrrolidone 46.1g
Low-substituted hydroxypropyl cellulose 39.2g
Mannitol 51.2g
Citric acid 39.2g
Sodium bicarbonate 39.2g
Aspartame 5.12g
Micropowder silica gel 10.2g
5% 30 POVIDONE K 30 BP/USP
30Ethanol solution is an amount of
Make 1000 altogether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100302881A CN101653587B (en) | 2008-08-19 | 2008-08-19 | Tangerine peel buccal tablets, oral disintegrating tablets and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100302881A CN101653587B (en) | 2008-08-19 | 2008-08-19 | Tangerine peel buccal tablets, oral disintegrating tablets and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101653587A CN101653587A (en) | 2010-02-24 |
| CN101653587B true CN101653587B (en) | 2011-06-15 |
Family
ID=41708187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100302881A Expired - Fee Related CN101653587B (en) | 2008-08-19 | 2008-08-19 | Tangerine peel buccal tablets, oral disintegrating tablets and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101653587B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133384B (en) * | 2011-03-02 | 2012-03-14 | 青岛大学 | Ginger and dried orange peel composition, preparation method thereof and application of ginger and dried orange peel composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy |
| CN103212053B (en) * | 2013-05-13 | 2015-07-01 | 于贺贺 | Medicine for treating carsickness and preparation method of medicine |
| CN103652089B (en) * | 2013-12-10 | 2015-06-03 | 华中农业大学 | Tea polysaccharide lozenge and preparation method thereof |
| CN104489434A (en) * | 2014-12-18 | 2015-04-08 | 东华大学 | Jelly for preventing carsickness and preparation method thereof |
| CN108617838A (en) * | 2017-03-22 | 2018-10-09 | 赖彦君 | A kind of carsickness-proof sugar lozenge and preparation method thereof |
| CN107496534A (en) * | 2017-10-16 | 2017-12-22 | 广东金山百草健康产业有限公司 | Beautiful millettia root cough stopping tablet, oral disnitegration tablet |
| CN107496893A (en) * | 2017-10-16 | 2017-12-22 | 广东金山百草健康产业有限公司 | South of the Five Ridges Triratna buccal tablet |
| CN108576810A (en) * | 2018-04-20 | 2018-09-28 | 谢寿文 | Dried orange peel process for preparing buccal lozenge |
| CN109771626A (en) * | 2019-01-29 | 2019-05-21 | 广东逸丰生态实业有限公司 | A kind of dendrobium candidum buccal tablets and preparation method thereof |
| CN114588209B (en) * | 2022-03-11 | 2023-05-02 | 国药葛洲坝中心医院 | Citrus reticulata Blanco extract and its application in preparing medicine for treating salivary gland diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824268A (en) * | 2005-12-23 | 2006-08-30 | 江西汇仁药业有限公司 | Spken invigorating qi replenishing dispersion solid medicinal preparation and its manufacturing method |
-
2008
- 2008-08-19 CN CN2008100302881A patent/CN101653587B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1824268A (en) * | 2005-12-23 | 2006-08-30 | 江西汇仁药业有限公司 | Spken invigorating qi replenishing dispersion solid medicinal preparation and its manufacturing method |
Non-Patent Citations (3)
| Title |
|---|
| 姜明旭,赵霞.<针刺配合橘皮汤治愈颅脑术后顽固性呃逆>.<山东中医杂志>.2002,第21卷(第1期),48. * |
| 郑小吉 ,王小平 ,詹晓如.<陈皮口腔崩解片中橙皮苷提取工艺研究 >.<中国现代中药 >.2008,第10卷(第6期),37-39. |
| 郑小吉,王小平,詹晓如.＜陈皮口腔崩解片中橙皮苷提取工艺研究＞.＜中国现代中药＞.2008,第10卷(第6期),37-39. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101653587A (en) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101653587B (en) | Tangerine peel buccal tablets, oral disintegrating tablets and application thereof | |
| CN102283999B (en) | Traditional Chinese medicine preparation for treating insomnia | |
| CN101327297B (en) | Chinese medicine composition for treating insomnia | |
| CN108403724A (en) | A kind of composition and preparation method thereof of adjustable mood | |
| CN104474341B (en) | A kind of pharmaceutical composition for treating ADHD in children | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN105995425A (en) | A medicinal and edible composition with the function of improving sleep and its application | |
| CN102210777B (en) | Chinese medicine composition for treating sepsis and preparation method thereof | |
| CN108294300A (en) | A kind of tranquilizing the mind dinner powder | |
| CN107243060A (en) | Chinese medicine composition for nursing one's health the human body deficiency of Yin and preparation method thereof | |
| CN103341074A (en) | Application of Yixuanning granules in preparation of medicaments for treating insomnia | |
| CN106237268A (en) | One treats schizoid pharmaceutical composition and application thereof | |
| CN102145059B (en) | Chinese patent medicament for treating intractable hypertension | |
| CN101468173B (en) | Chinese medicinal composition for treating children's indigestion and preparation method thereof | |
| CN104398788A (en) | Traditional Chinese medicine electuary for treating insomnia and preparation method for traditional Chinese medicine electuary | |
| CN104324134B (en) | One kind improves microcirculatory Chinese medicine composition and preparation method thereof | |
| CN102441103B (en) | Medicine for treating insomnia | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN104857414A (en) | Medicine composite for treating chronic simple rhinitis | |
| CN102579830A (en) | Immunization therapy for treating psoriasis by snuffing of Chinese medicines and sweat steam | |
| CN103830649B (en) | A kind of medicine for the treatment of chronic alcoholism and preparation method thereof | |
| CN103961609A (en) | Difenidol hydrochloride and preparation method thereof | |
| CN102671052B (en) | Chinese medicinal composition for treating Meniere's syndrome | |
| CN104857496B (en) | A kind of Chinese traditional medicine navel for the treatment of children's's wind-cold type diarrhoea pastes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110615 Termination date: 20140819 |
|
| EXPY | Termination of patent right or utility model |